CIPH Ciphergen Biosystems (MM)

FREMONT, Calif., April 11 /PRNewswire-FirstCall/ -- Ciphergen Biosystems (NASDAQ:CIPH) today announced that the company and collaborators from M.D. Anderson Cancer Center at the University of Texas will present data supporting Ciphergen's ovarian cancer diagnostics program at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) to be held April 14-18, 2007, at the Los Angeles Convention Center, Los Angeles, CA. To follow are the presentation details: Title: Proteomics discovery of urinary biomarkers for early stage ovarian cancer Abstract Number: 594 Poster Session: Sunday, April 15, 2007, 8:00 AM - 12:00 PM About Ciphergen Ciphergen Biosystems, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Ciphergen, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology, cardiology and women's health with an initial focus in ovarian cancer. Based in Fremont, California, more information about Ciphergen can be found on the Web at http://www.ciphergen.com/. Safe Harbor Statement This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in Ciphergen's Form 10-K for the year ended Dec. 31, 2006, and in Ciphergen's periodic reports on Form 10-Q and Form 8-K. Ciphergen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc., +1-510-505-2297; or media, Lori Murray of WeissComm Partners, +1-415-946-1070, for Ciphergen Biosystems, Inc. Web site: http://www.ciphergen.com/

Copyright